Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature

Bibliographic Details
Main Authors:	Jacopo Lolli, Francesca Tessari, Franco Berti, Marco Fusella, Davide Fiorentin, Davide Bimbatti, Umberto Basso, Fabio Busato
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Oncology
Subjects:	cabozantinib radionecrosis (RN) stereotacic radiation immunotherapy radiosurgery
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1278074/full

Similar Items

Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature
by: Jacopo Lolli, et al.
Published: (2023-03-01)

Quantitative MR Perfusion for the Differentiation of Recurrence and Radionecrosis in Hypoperfusion and Hyperperfusion Brain Metastases After Gamma Knife Radiosurgery
by: Yang Yunqi, et al.
Published: (2022-03-01)

Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure
by: Justin Leu, et al.
Published: (2023-04-01)

Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure
by: Justin Leu, et al.
Published: (2023-03-01)

Cerebral Radionecrosis in Patients with Nasopharyngeal Carcinoma
by: Ying-Che Hsu, et al.
Published: (2005-10-01)

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
by: Roger Sun, et al.
Published: (2017-12-01)

Stereotactic radiotherapy for brain metastases: predictive factors of radionecrosis
by: Benoît Calderon, et al.
Published: (2023-07-01)

Stereotactic Radiotherapy for Brain Metastases: Imaging Tools and Dosimetric Predictive Factors for Radionecrosis
by: Marco Lupattelli, et al.
Published: (2020-07-01)

Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform
by: Marta Scorsetti, et al.
Published: (2023-02-01)

Treatment of Laryngeal Radionecrosis with Hyperbaric Oxygen Therapy: A Case Report
by: Ying-Che Hsu, et al.
Published: (2005-02-01)

Radionecrosis cerebral en un adulto
by: Duniel Abreu Casas, et al.
Published: (2024-02-01)

A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases
by: Julian Mangesius, et al.
Published: (2022-12-01)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
by: Michael H. Storandt, et al.
Published: (2022-10-01)

A Multidimensional Connectomics- and Radiomics-Based Advanced Machine-Learning Framework to Distinguish Radiation Necrosis from True Progression in Brain Metastases
by: Yilin Cao, et al.
Published: (2023-08-01)

Long-term Outcomes after Salvage Stereotactic Radiosurgery (SRS) following In-Field Failure of Initial SRS for Brain Metastases
by: Nitesh Rana, et al.
Published: (2017-11-01)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
by: Rathi N, et al.
Published: (2020-05-01)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
by: Anastasia A. Sachkova, et al.
Published: (2022-12-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases
by: J. A. Crouzen, et al.
Published: (2023-03-01)

Current status and recent advances in reirradiation of glioblastoma
by: Giuseppe Minniti, et al.
Published: (2021-02-01)

Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats
by: Yu-Chuen Huang, et al.
Published: (2023-03-01)

Case Report: Contribution of [18F]FET PET in differential diagnosis between radionecrosis and progression in metastasis—reproducibility and superiority of dynamic acquisitions
by: Aurélien Callaud, et al.
Published: (2024-02-01)

Experience of Using Hyperbaric Oxygenation in the Treatment of Radionecrosis That Developed as a Complication of Stereotactic Radiosurgical Treatment of Meningioma on the Example of a Clinical Case
by: A. S. Tokarev, et al.
Published: (2021-01-01)

Interest of routine MR spectroscopic techniques for differential diagnosis between radionecrosis and progression of brain tumor lesions
by: Federico De Lucia, et al.
Published: (2022-01-01)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
by: Tyler Gutschenritter, et al.
Published: (2020-12-01)

Neurotoxicity from Old and New Radiation Treatments for Brain Tumors
by: Riccardo Soffietti, et al.
Published: (2023-06-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
by: Minas P. Economides, et al.
Published: (2020-11-01)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
by: Hironao Okubo, et al.
Published: (2022-11-01)

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
by: Igor Richter, et al.
Published: (2022-03-01)

RET-mutated recurrent leiomyosarcoma treated with cabozantinib: a case report
by: Carlos E. Salazar-Mejía, et al.
Published: (2023-07-01)

Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
by: H. M. N. Chen, et al.
Published: (2020-11-01)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
by: Shanshan Deng, et al.
Published: (2021-10-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022-06-01)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
by: Shreya Kumar, et al.
Published: (2023-09-01)

Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
by: Maria I. Volkova, et al.
Published: (2023-08-01)

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
by: Lorenza Rimassa, et al.
Published: (2021-12-01)